Inclusion Criteria:

- Men and women 18 and older

- Diagnosis of any solid tumor

- ECOG performance status score 0-1

- Prior chemo-therapy, immunotherapy or radiotherapy with at least 4 weeks since the
last treatment

- Treatment with VEGFR2 or HER1 TKI allowed but not both (for instance Avastin or
Tarceva, but not both)

Exclusion Criteria:

- Treatment with other TKIs within the past 4 weeks

- Patients with brain metastasis

- Patients with centrally located squamous cell carcinoma of the lung

- Major gastrointestinal surgery which may affect absorption of the drug

- Any surgery within last 4 weeks

- History of thromboembolism

- Severe unmanageable diarrhea

- Subjects in Part B will have Non-Small Cell Lung Cancer (NSCLC)

- Part B/Cohort I erlotinib-naive subjects

- Part B/Cohort II subjects who have experienced disease progression while receiving
erlotinib (erlotinib-resistant subjects)